Avalon GloboCare (ALBT) Competitors

$0.34 -0.01 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 +0.00 (+0.35%)

As of 05:19 PM Eastern

ALBT vs. PHXM, MTEX, IMNN, BON, and BIVI

Should you buy Avalon GloboCare stock or one of its competitors? MarketBeat compares Avalon GloboCare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalon GloboCare include PHAXIAM Therapeutics (PHXM), Mannatech (MTEX), Imunon (IMNN), Bon Natural Life (BON), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry.

How does Avalon GloboCare compare to PHAXIAM Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Avalon GloboCare	N/A	N/A	-74.36%

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PHAXIAM Therapeutics has higher earnings, but lower revenue than Avalon GloboCare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Avalon GloboCare	$1.26M	2.25	-$18.26M	-$3.51	N/A

In the previous week, Avalon GloboCare had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Avalon GloboCare and 0 mentions for PHAXIAM Therapeutics. Avalon GloboCare's average media sentiment score of 1.42 beat PHAXIAM Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Avalon GloboCare	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Summary

Avalon GloboCare beats PHAXIAM Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Avalon GloboCare compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Mannatech has higher revenue and earnings than Avalon GloboCare. Mannatech is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$8.00	N/A
Avalon GloboCare	$1.26M	2.25	-$18.26M	-$3.51	N/A

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Mannatech had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 4 mentions for Mannatech and 3 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 1.42 beat Mannatech's score of 0.15 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Overall Sentiment
Mannatech	Neutral
Avalon GloboCare	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avalon GloboCare has a net margin of 0.00% compared to Mannatech's net margin of -14.08%. Avalon GloboCare's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-14.08%	-398.35%	-45.63%
Avalon GloboCare	N/A	N/A	-74.36%

Summary

Mannatech beats Avalon GloboCare on 7 of the 13 factors compared between the two stocks.

How does Avalon GloboCare compare to Imunon?

Avalon GloboCare (NASDAQ:ALBT) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Avalon GloboCare has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Imunon has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Imunon has lower revenue, but higher earnings than Avalon GloboCare. Imunon is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.25	-$18.26M	-$3.51	N/A
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Imunon had 7 more articles in the media than Avalon GloboCare. MarketBeat recorded 10 mentions for Imunon and 3 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 1.42 beat Imunon's score of 0.62 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Positive
Imunon	Positive

Imunon has a consensus target price of $10.00, suggesting a potential upside of 301.61%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Avalon GloboCare's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Imunon	N/A	-341.23%	-153.79%

Summary

Avalon GloboCare and Imunon tied by winning 7 of the 14 factors compared between the two stocks.

How does Avalon GloboCare compare to Bon Natural Life?

Avalon GloboCare (NASDAQ:ALBT) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Avalon GloboCare has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Bon Natural Life	N/A	N/A	N/A

Bon Natural Life has higher revenue and earnings than Avalon GloboCare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.25	-$18.26M	-$3.51	N/A
Bon Natural Life	$18.67M	0.57	-$2M	N/A	N/A

In the previous week, Avalon GloboCare had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 3 mentions for Avalon GloboCare and 2 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.46 beat Avalon GloboCare's score of 1.42 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalon GloboCare	Positive
Bon Natural Life	Positive

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bon Natural Life beats Avalon GloboCare on 5 of the 9 factors compared between the two stocks.

How does Avalon GloboCare compare to BioVie?

Avalon GloboCare (NASDAQ:ALBT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avalon GloboCare has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, BioVie has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, BioVie had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 4 mentions for BioVie and 3 mentions for Avalon GloboCare. BioVie's average media sentiment score of 1.47 beat Avalon GloboCare's score of 1.42 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalon GloboCare	Positive
BioVie	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioVie has lower revenue, but higher earnings than Avalon GloboCare. BioVie is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	2.25	-$18.26M	-$3.51	N/A
BioVie	N/A	N/A	-$17.54M	-$3.25	N/A

Avalon GloboCare's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
BioVie	N/A	-101.15%	-90.18%

Summary

BioVie beats Avalon GloboCare on 6 of the 11 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALBT vs. The Competition

Export

Metric	Avalon GloboCare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.84M	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.10	18.21	20.16	25.24
Price / Sales	2.25	283.14	541.97	73.15
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-0.19	6.72	9.81	6.90
Net Income	-$18.26M	$24.16M	$3.56B	$333.88M
7 Day Performance	-14.80%	3.87%	0.29%	0.02%
1 Month Performance	-14.05%	-3.02%	-0.99%	1.75%
1 Year Performance	-90.61%	68.84%	36.15%	32.64%

Avalon GloboCare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALBT Avalon GloboCare	1.0453 of 5 stars	$0.34 -1.8%	N/A	-90.8%	$2.84M	$1.26M	N/A	5	Positive News Earnings Report Short Interest Decrease Gap Down
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MTEX Mannatech	0.2486 of 5 stars	$5.41 +10.6%	N/A	-58.6%	$10.44M	$108.04M	N/A	250	News Coverage Earnings Report
IMNN Imunon	2.1055 of 5 stars	$2.55 -5.7%	$10.00 +292.9%	-72.3%	$10.15M	N/A	N/A	30	News Coverage Earnings Report Gap Down
BON Bon Natural Life	1.1441 of 5 stars	$1.21 -0.8%	N/A	N/A	$9.84M	$18.67M	N/A	100	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALBT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalon GloboCare (ALBT) Competitors

ALBT vs. PHXM, MTEX, IMNN, BON, and BIVI

How does Avalon GloboCare compare to PHAXIAM Therapeutics?

Summary

How does Avalon GloboCare compare to Mannatech?

Summary

How does Avalon GloboCare compare to Imunon?

Summary

How does Avalon GloboCare compare to Bon Natural Life?

Summary

How does Avalon GloboCare compare to BioVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalon GloboCare (ALBT) Competitors

ALBT vs. PHXM, MTEX, IMNN, BON, and BIVI

How does Avalon GloboCare compare to PHAXIAM Therapeutics?

Is PHXM or ALBT more profitable?

Do insiders and institutionals have more ownership in PHXM or ALBT?

Which has better valuation and earnings, PHXM or ALBT?

Does the media prefer PHXM or ALBT?

Do analysts prefer PHXM or ALBT?

Which has more volatility & risk, PHXM or ALBT?

Summary

How does Avalon GloboCare compare to Mannatech?

Which has more volatility & risk, MTEX or ALBT?

Which has better valuation and earnings, MTEX or ALBT?

Do insiders and institutionals have more ownership in MTEX or ALBT?

Does the media prefer MTEX or ALBT?

Do analysts prefer MTEX or ALBT?

Is MTEX or ALBT more profitable?

Summary

How does Avalon GloboCare compare to Imunon?

Which has more volatility & risk, ALBT or IMNN?

Which has stronger valuation and earnings, ALBT or IMNN?

Do institutionals and insiders have more ownership in ALBT or IMNN?

Does the media favor ALBT or IMNN?

Do analysts recommend ALBT or IMNN?

Is ALBT or IMNN more profitable?

Summary

How does Avalon GloboCare compare to Bon Natural Life?

Which has more risk & volatility, ALBT or BON?

Is ALBT or BON more profitable?

Which has preferable earnings and valuation, ALBT or BON?

Does the media refer more to ALBT or BON?

Do insiders & institutionals have more ownership in ALBT or BON?

Do analysts recommend ALBT or BON?

Summary

How does Avalon GloboCare compare to BioVie?

Do insiders & institutionals have more ownership in ALBT or BIVI?

Which has more risk & volatility, ALBT or BIVI?

Does the media refer more to ALBT or BIVI?

Do analysts recommend ALBT or BIVI?

Which has preferable earnings and valuation, ALBT or BIVI?

Is ALBT or BIVI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools